NYU Langone study finds the hallucinogenic drug psilocybin, when combined with counseling, relieves depression and anxiety in cancer patients.
NYU Langone’s High School Bioethics Project examines PTSD and the ethical implications of using psychedelics like psilocybin to treat symptoms. Learn More
NYU Langone study finds a psychedelic drug improved emotional distress in people with cancer for nearly five years after treatment.
NYU Langone’s Dr. Michael P. Bogenschutz, Dr. Stephen Ross, and colleagues explore therapeutic agents such as psilocybin, cannabidiol, and MDMA.
NYU Langone psychiatrist Dr. Stephen Ross sees potential for psychedelic drugs to treat anxiety, depression, and other mental health disorders.
Three NYU Langone doctors discuss the impact of the COVID-19 pandemic on healthcare and new advances in their fields.
Teachers may use our learning scenarios, or short bioethics primers, to supplement their curricula. Learn More
NYU Langone’s Department of Psychiatry conducts research to further understand substance use disorder causes and treatments. Learn More
NYU Langone Health opens a comprehensive Center for Psychedelic Medicine, building on its leadership position in this resurging field.
Physician–scientists in NYU Langone’s Department of Psychiatry offer a postdoctoral psychedelic medicine research training program. Learn More